Search

Displaying results 4111 - 4120 of 9670 in total
  1. Drug

    Dexloxiglumide

    go.drugbank.com/drugs/DB04856
    Investigational

    As the D-isomer of loxiglumide, it retains all pharmacological properties of loxiglumide but is more potent. … Dexloxiglumide is a selective cholecystokinin type A (CCKA) receptor antagonist in phase III testing by Rottapharm in Europe only, as U.S. trials have been discontinued.

  2. Drug

    Polyinosinic-polycytidylic acid

    go.drugbank.com/drugs/DB16467
    Investigational

  3. Drug

    Chenopodium ambrosioides pollen

    go.drugbank.com/drugs/DB10479
    Approved

    Chenopodium ambrosioides pollen is the pollen of the Chenopodium ambrosioides plant. Chenopodium ambrosioides pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS128873
  4. Drug

    Chenopodium botrys pollen

    go.drugbank.com/drugs/DB10838
    Approved

    Chenopodium botrys pollen is the pollen of the Chenopodium botrys plant. Chenopodium botrys pollen is mainly used in allergenic testing.

    Mixtures: Treatment Set TS128873
  5. Drug

    Nomifensine

    go.drugbank.com/drugs/DB04821
    ApprovedWithdrawn

    Nomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia. … Approval of the NDA for Merital capsules was withdrawn on March 20, 1992 (see the Federal Register of March 20, 1992 (57 FR 9729)). Also withdrawn from the Canadian and UK markets.

  6. Drug

    Etesevimab

    go.drugbank.com/drugs/DB15897
    Investigational

    Etesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain. … progressing to severe COVID-19:[L40179] this EUA later expanded in December 2021 to include all younger children at high risk, including newborns.

  7. Drug

    rhIGFBP-3

    go.drugbank.com/drugs/DB05897
    Investigational

    It is developed by Insmed and is currently under phase I of the clinical trial. … rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models

  8. Drug

    Anacaulase

    go.drugbank.com/drugs/DB17449
    ApprovedInvestigational

    It is mostly composed (80-95% w/w) of proteins such as stem bromelain, ananain, jacalin-like lectin, bromelain inhibitors, and phytocystatin inhibitor, as well as saccharides, as both free monosaccharides … Therefore, enzymatic alternatives such as anacaulase can lead to better clinical outcomes.

  9. Drug

    iCo-007

    go.drugbank.com/drugs/DB05268
    Investigational

    ) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR). … iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis

  10. Drug

    Aspergillus flavus

    go.drugbank.com/drugs/DB10694
    Approved

    Aspergillus flavus is a fungus which can provoke allergic reactions. Aspergillus flavus extract is used in allergenic testing.

    Mixtures: Treatment Set TS333938